Blood draws are among the most performed clinical procedures globally, yet they remain surprisingly error-prone — painful, inconsistent, and increasingly constrained by phlebotomist shortages. A multicenter trial now provides substantive evidence that an autonomous robotic system can perform venipuncture with clinical-grade reliability, even in patient populations historically considered technically challenging.
The ADOPT trial enrolled 1,786 patients across outpatient phlebotomy departments in the Netherlands, divided into two cohorts. The first cohort of 153 patients established analytical equivalence between robot-collected and manually collected samples — no statistically significant differences emerged for activated partial thromboplastin time, prothrombin time, lactate dehydrogenase, aspartate transaminase, or platelet count, which are among the most variability-sensitive assays in routine hematology and coagulation panels. The second, larger cohort of 1,633 patients evaluated real-world performance: the autonomous robotic phlebotomy device (ARPD), which uses multimodal imaging to locate veins, achieved a first-stick success rate of 94.5% overall — and notably held at 92.7% in patients with difficult venous access, 97.4% in obese patients, and 93.4% in those aged 65 or older. Adverse events were reported as mild and infrequent.
These findings carry meaningful implications for health system design. Phlebotomy failure rates in conventional settings can reach 20–25% in challenging populations, often requiring multiple attempts that increase patient discomfort and hemolysis risk. That a robotic system maintains near-equivalent performance across obesity and advanced age — two factors that reliably complicate manual draws — suggests the multimodal imaging approach may be genuinely compensating for anatomical variability rather than merely replicating average-case performance. The study's limitation is its single-country, outpatient-only design; performance in inpatient, pediatric, or emergency settings remains uncharacterized. This is nonetheless a well-powered, methodologically rigorous trial and represents a legitimate step toward clinical automation of a high-volume, workforce-constrained procedure.